TY  - CHAP
M1  - Book, Section
TI  - Management of Oropharyngeal Squamous Cell Carcinoma
A1  - Clump, David A.
A1  - Bauman, Julie E.
A1  - Ferris, Robert L.
A2  - Morita, Shane Y.
A2  - Balch, Charles M.
A2  - Klimberg, V. Suzanne
A2  - Pawlik, Timothy M.
A2  - Posner, Mitchell C.
A2  - Tanabe, Kenneth K.
Y1  - 2018
N1  - 
T2  - Textbook of Complex General Surgical Oncology
AB  - Approximately  41,000  cases  of  head  and  neck  squamous  cell  carcinoma  (HNSCC)  are  diagnosed  annually  in  the  United  States,  of  which  approximately  one-third  arises  within  the  oropharynx.1  Located  posterior  to  the  oral  cavity  and  between  the  nasopharynx  and  larynx,  the  oropharynx  is  critical  in  maintaining  normal  speech  and  swallowing.  Its  main  components  include  the  soft  palate,  posterior  and  lateral  pharyngeal  walls,  faucial  arches,  tonsillar  fossa,  as  well  as  the  base  of  tongue  (which  anchors  to  the  hyoid  bone  at  the  inferior  border  of  the  oropharynx).  Its  nonrestraining  soft  tissue  boundaries  as  well  as  its  rich  lymphatic  supply  allow  the  escape  of  malignant  cells,  resulting  in  the  majority  of  patients  presenting  with  advanced  disease  (stage  III  or  IV).1  Treatment  often  consists  of  surgical  resection  followed  by  adjuvant  radiotherapy  (RT)  with  or  without  chemotherapy;  however,  successful  nonsurgical  strategies  have  been  developed  over  recent  years  through  the  refinement  of  RT  techniques  and/or  the  use  of  combination  chemoradiotherapy  (CRT).2  Recently,  however,  the  introduction  of  minimally  invasive  techniques  has  rekindled  interest  in  surgical  therapy.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesssurgery.mhmedical.com/content.aspx?aid=1145758917
ER  -